Pathway Capital Management LP Takes Position in CRISPR Therapeutics AG $CRSP

Pathway Capital Management LP purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 50,049 shares of the company’s stock, valued at approximately $3,244,000. CRISPR Therapeutics accounts for approximately 15.9% of Pathway Capital Management LP’s holdings, making the stock its 4th biggest position. Pathway Capital Management LP owned about 0.06% of CRISPR Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in shares of CRISPR Therapeutics by 28.2% during the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock worth $4,856,000 after acquiring an additional 31,392 shares during the period. AQR Capital Management LLC bought a new stake in shares of CRISPR Therapeutics during the first quarter valued at approximately $861,000. Woodline Partners LP boosted its position in shares of CRISPR Therapeutics by 34.3% during the first quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after purchasing an additional 34,883 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in CRISPR Therapeutics by 26.9% in the second quarter. Janney Montgomery Scott LLC now owns 13,585 shares of the company’s stock worth $661,000 after purchasing an additional 2,882 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in CRISPR Therapeutics by 18.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,336 shares of the company’s stock worth $162,000 after purchasing an additional 519 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $51.31 on Tuesday. The company has a 50-day simple moving average of $55.08 and a two-hundred day simple moving average of $58.27. The stock has a market capitalization of $4.89 billion, a PE ratio of -9.18 and a beta of 1.72. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.15. The company had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRSP. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Friday. Royal Bank Of Canada boosted their price objective on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 11th. Wells Fargo & Company set a $75.00 price objective on shares of CRISPR Therapeutics in a report on Monday, October 13th. Finally, Bank of America decreased their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Twelve analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $67.85.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 60,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the transaction, the chief executive officer owned 134,201 shares in the company, valued at $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.